Close Menu

Diagnostics Business, Policy & Funding

Breaking news on Diagnostics business, policy & funding.

The investment bank sees the potential for strong revenue growth over time as Oncocyte expands its product portfolio and launches new tests.

The company's HCCscreen assay will be used in a liver cancer screening public health initiative, generating real-world data on the test's clinical validity and impact.

The next-generation sequencing-based panel comprises more than 50 genes and disorders known to cause hereditary anemias, such as pyruvate kinase deficiency.

The RT-PCR-based test was first authorized earlier this year for the detection of SARS-CoV-2 nucleic acid in specimens collected by a healthcare provider.

The test uses a targeted methylation sequencing panel to detect more than 50 cancer types across all stages and pinpoint a cancer's tissue of origin.